The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Gd-DO 3A     2-[4,7- bis(carboxylatomethyl)-1,4,7- triaza...

This record was replaced with 107830.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

  • Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging [1].
  • These results indicate excellent safety and efficacy for use of gadoteridol in children with suspected intracranial or spinal disease [2].
  • MATERIALS AND METHODS: In 175 consecutive patients with a musculoskeletal mass, dynamic contrast-enhanced subtraction MR imaging was performed after administration of 0.1 mmol per kilogram of body weight gadopentetate dimeglumine or gadoteridol [3].
  • In phase II and III trials of gadoteridol (Gd-HP-D03A), a new nonionic, low-osmolar contrast agent, 40 patients with intracranial neoplasms underwent magnetic resonance (MR) imaging with experimental doses of 0.05-0.3 mmol/kg [4].
  • Adverse clinical events possibly or probably associated with injection of gadoteridol were seen in 18 of 411 patients (4.4%); the most common were dysgeusia and mild nausea, and all abated without residual effects [5].

High impact information on 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

  • MATERIALS AND METHODS: Forty consecutive patients with cerebrovascular disease in the differential diagnosis were evaluated with fluoroscopically triggered 3D MR angiography (gadoteridol dose range, 0.1-0.3 mmol per kilogram of body weight; mean acquisition time, 40 second +/- 8 [SD]) [6].
  • MATERIALS AND METHODS: Twenty-five consecutive patients suspected of having renal artery disease were evaluated with the fluoroscopically triggered technique by using a mean dose of 0.18 mmol/kg gadoteridol [7].
  • PURPOSE: To determine if hepatic metastases can be distinguished from cavernous hemangiomas by pattern analysis of magnetic resonance (MR) images obtained prior to and following administration of gadoteridol at standard (0.1 mmol/kg) and triple (0.3 mmol/kg) doses [1].
  • In this phase III study, 411 adult patients with suspected intracranial or spinal disease underwent magnetic resonance (MR) imaging before and after intravenous injection of 0.1 mmol/kg gadoteridol (gadolinium 1,4,7-tris [carboxymethyl]-10-[2'-hydroxypropyl]-1,4,7,10-tetraazacyclododecane+ ++) [5].
  • Improved enhancement, detection, and delineation of central nervous system (CNS) neoplasms resulting from increased injected doses of gadoteridol have the potential to be clinically significant and may justify the possibly higher cost of increased contrast material dosage [4].

Chemical compound and disease context of 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid


Biological context of 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

  • MATERIALS AND METHODS: Dynamic contrast-enhanced MRI (DCE-MRI) was performed in an experimental cancer model with the use of the novel protein-binding agent B22956/1, a low molecular contrast agent (ProHance), and a macromolecular contrast medium, albumin-(Gd-DTPA) [10].
  • To assess the safety and pharmacokinetics of gadoteridol injection (0.5 M) in 18 healthy male volunteers in a phase I clinical trial [11].
  • The rate of adverse events possibly or probably related to gadoteridol was 4.0% (vasodilation [facial flushing], 1 patient; nausea, 3 patients; urticaria, 2 patients) [12].
  • Capillary permeability was resolved from uptake data for eight rat organs with gadoteridol, which is a stable, well-tolerated, nonionic, highly water soluble, gadolinium-containing, magnetic resonance imaging contrast agent [13].
  • In mice, the acute intravenous LD50 for gadoteridol (0.5 M) injection was 11 to 14 mmol/kg, and the intravenous minimal lethal dose in rats was greater than 10 mmol/kg [14].

Anatomical context of 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid


Associations of 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid with other chemical compounds


Gene context of 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

  • 19 patients with clinically active rheumatoid arthritis involving a knee were scanned twice, one week apart, using 0.1 mmol/kg of gadoteridol (ProHance) on the first occasion and 0.3 mmol/kg on the second [23].
  • Ten MS patients underwent 1.5-T MR imaging of the brain with spin-echo T1-weighted sequences with and without MT, repeated after 0.1 mmol/kg of an usual two-compartment paramagnetic contrast agent (Gadoteridol, Gd-HP-DO3A) [24].

Analytical, diagnostic and therapeutic context of 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid


  1. Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging. Mitchell, D.G., Saini, S., Weinreb, J., De Lange, E.E., Runge, V.M., Kuhlman, J.E., Parisky, Y., Johnson, C.D., Brown, J.J., Schnall, M. Radiology. (1994) [Pubmed]
  2. Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease. Ball, W.S., Nadel, S.N., Zimmerman, R.A., Byrd, S.E., Dietrich, R.B., Prenger, E.C., Drayer, B.P., Nelson, M.D., Morgan, F.W., Altman, N.R. Radiology. (1993) [Pubmed]
  3. Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? van der Woude, H.J., Verstraete, K.L., Hogendoorn, P.C., Taminiau, A.H., Hermans, J., Bloem, J.L. Radiology. (1998) [Pubmed]
  4. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Yuh, W.T., Fisher, D.J., Engelken, J.D., Greene, G.M., Sato, Y., Ryals, T.J., Crain, M.R., Ehrhardt, J.C. Radiology. (1991) [Pubmed]
  5. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Runge, V.M., Bradley, W.G., Brant-Zawadzki, M.N., Carvlin, M.J., DeSimone, D.N., Dean, B.L., Dillon, W.P., Drayer, B.P., Flanders, A.E., Harms, S.E. Radiology. (1991) [Pubmed]
  6. Carotid arteries: maximizing arterial to venous contrast in fluoroscopically triggered contrast-enhanced MR angiography with elliptic centric view ordering. Huston, J., Fain, S.B., Riederer, S.J., Wilman, A.H., Bernstein, M.A., Busse, R.F. Radiology. (1999) [Pubmed]
  7. Fluoroscopically triggered contrast-enhanced three-dimensional MR angiography with elliptical centric view order: application to the renal arteries. Wilman, A.H., Riederer, S.J., King, B.F., Debbins, J.P., Rossman, P.J., Ehman, R.L. Radiology. (1997) [Pubmed]
  8. Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents. Marzola, P., Ramponi, S., Nicolato, E., Lovati, E., Sandri, M., Calderan, L., Crescimanno, C., Merigo, F., Sbarbati, A., Grotti, A., Vultaggio, S., Cavagna, F., Lorusso, V., Osculati, F. Investigative radiology. (2005) [Pubmed]
  9. Acute cardiotoxicity of gadolinium-based contrast media: findings in the isolated rat heart. Akre, B.T., Dunkel, J.A., Hustvedt, S.O., Refsum, H. Academic radiology. (1997) [Pubmed]
  10. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. Preda, A., Novikov, V., Möglich, M., Turetschek, K., Shames, D.M., Brasch, R.C., Cavagna, F.M., Roberts, T.P. Journal of magnetic resonance imaging : JMRI. (2004) [Pubmed]
  11. Pharmacokinetic behavior of gadoteridol injection. McLachlan, S.J., Eaton, S., De Simone, D.N. Investigative radiology. (1992) [Pubmed]
  12. Phase III clinical studies with gadoteridol for the evaluation of neurologic pathology. A European perspective. Seiderer, M. Investigative radiology. (1992) [Pubmed]
  13. A multi-organ, axially distributed model of capillary permeability for a magnetic resonance imaging contrast agent. Eaton, S.M., Wedeking, P., Tweedle, M.F., Eckelman, W.C. Journal of pharmaceutical sciences. (1993) [Pubmed]
  14. Summary of preclinical safety evaluation of gadoteridol injection. Soltys, R.A. Investigative radiology. (1992) [Pubmed]
  15. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Saito, R., Krauze, M.T., Bringas, J.R., Noble, C., McKnight, T.R., Jackson, P., Wendland, M.F., Mamot, C., Drummond, D.C., Kirpotin, D.B., Hong, K., Berger, M.S., Park, J.W., Bankiewicz, K.S. Exp. Neurol. (2005) [Pubmed]
  16. Diffusion into human intervertebral disks studied with MR and gadoteridol. Akansel, G., Haughton, V.M., Papke, R.A., Censky, S. AJNR. American journal of neuroradiology. (1997) [Pubmed]
  17. Usefulness of magnetic resonance imaging early after acute myocardial infarction. Kramer, C.M., Rogers, W.J., Geskin, G., Power, T.P., Theobald, T.M., Hu, Y.L., Reichek, N. Am. J. Cardiol. (1997) [Pubmed]
  18. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Gibby, W.A., Gibby, K.A., Gibby, W.A. Investigative radiology. (2004) [Pubmed]
  19. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T. Brekenfeld, C., Foert, E., Hundt, W., Kenn, W., Lodeann, K.P., Gehl, H.B. Investigative radiology. (2001) [Pubmed]
  20. Indirect MR lymphangiography of the head and neck using conventional gadolinium contrast: A pilot study in humans. Loo, B.W., Draney, M.T., Sivanandan, R., Ruehm, S.G., Pawlicki, T., Xing, L., Herfkens, R.J., Le, Q.T. Int. J. Radiat. Oncol. Biol. Phys. (2006) [Pubmed]
  21. Comparison of aerosolized gadoteridol and gadopentetate dimeglumine for magnetic resonance ventilation imaging of the lung. Haage, P., Karaagac, S., Adam, G., Glowinski, A., Günther, R.W. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. (2001) [Pubmed]
  22. A noninvasive method for monitoring renal status at bedside. Tweedle, M.F., Zhang, X., Fernandez, M., Wedeking, P., Nunn, A.D., Strauss, H.W. Investigative radiology. (1997) [Pubmed]
  23. Advantages of an increased dose of MRI contrast agent for enhancing inflammatory synovium. Oliver, C., Speake, S., Watt, I., Dieppe, P., Ratcliffe, G. Clinical radiology. (1996) [Pubmed]
  24. Evaluation of Gd-enhancement in brain MR of multiple sclerosis: image subtraction with and without magnetization transfer. Sardanelli, F., Losacco, C., Iozzelli, A., Renzetti, P., Rosso, E., Parodi, R.C., Bonetti, M., Murialdo, A. European radiology. (2002) [Pubmed]
  25. MR arthrography of the glenohumeral joint: two concentrations of gadoteridol versus Ringer solution as the intraarticular contrast material. Binkert, C.A., Zanetti, M., Gerber, C., Hodler, J. Radiology. (2001) [Pubmed]
  26. Multislice first-pass myocardial perfusion imaging on a conventional clinical scanner. Walsh, E.G., Doyle, M., Lawson, M.A., Blackwell, G.G., Pohost, G.M. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. (1995) [Pubmed]
  27. Sequential dynamic susceptibility contrast MR experiments in human brain: residual contrast agent effect, steady state, and hemodynamic perturbation. Levin, J.M., Kaufman, M.J., Ross, M.H., Mendelson, J.H., Maas, L.C., Cohen, B.M., Renshaw, P.F. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. (1995) [Pubmed]
  28. Three-dimensional MR pulmonary perfusion imaging and angiography with an injection of a new blood pool contrast agent B-22956/1. Zheng, J., Carr, J., Harris, K., Saker, M.B., Cavagna, F.M., Maggioni, F., Laub, G., Li, D., Finn, J.P. Journal of magnetic resonance imaging : JMRI. (2001) [Pubmed]
WikiGenes - Universities